– USA, TX – Coya Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced the appointments of Dr. Hideki Garren, M.D., Ph.D., Chief Medical Officer of Prothena and Dr. Dov Goldstein, M.D., CFO and Chief Business Officer of Indapta, to its Board of Directors, effective immediately, bringing the Board five members.
“We are pleased to welcome these world-class leaders to our board; their expertise in research and development of neurological and autoimmune diseases, as well as in global business development will be invaluable to Coya’s future growth,” said CEO, Dr. Howard Berman. “We look forward to working with Dr. Garren and Dr. Goldstein as we continue to advance novel therapeutics–delivering on our mission to improve outcomes and the standard of care for patients with amyotrophic lateral sclerosis and neurodegenerative diseases.”
About Dr. Hideki Garren
Dr. Garren has 20 years of experience in the biopharmaceutical industry, spanning all aspects of novel drug development from discovery, to early-stage clinical trials, to late-stage clinical trials, to commercialization. He currently serves as the Chief Medical Officer for Prothena, a late-stage clinical company with expertise in protein dysregulation, focusing on rare peripheral amyloid and neurodegenerative diseases. From 2013 to 2020, he served as VP, Global Head of Neuroimmunology for F. Hoffmann-La Roche & Genentech Inc., where he led the teams which conducted the Ocrevus Phase III trials for multiple sclerosis and Enspryng Phase III trials for the rare disease neuromyelitis optica spectrum disorder. Previously, Dr. Garren served as Executive Director, Translational Medicine Expert in neuroscience for Novartis Pharma.
In 2002, Dr. Garren co-founded Bayhill Therapeutics, centered on a novel therapeutic platform for treating autoimmune diseases which he co-discovered while at Stanford University, and served as EVP, CSO, and COO. He served as adjunct clinical faculty in the Department of Neurology at Stanford University from 1997 to 2009.
Dr. Garren earned his Bachelor of Science degree from the California Institute of Technology and his M.D. and Ph.D. from the University of California Los Angeles.
About Dr. Dov Goldstein
Dr. Goldstein brings over 20 years of strategic financial and operational experience within the healthcare sector. He currently serves as the CFO and Chief Business Officer of Indapta Therapeutics, a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRy-deficient natural killer cell therapy to treat multiple types of cancer. Dr. Goldstein was previously CEO of RIGImmune. Before that, he served as the CFO at Schrödinger, LLC from 2017 to 2018.
Dr. Goldstein held various leadership roles at Aisling Capital, a private investment firm, from 2006 to 2017, serving as its Managing Partner from 2014 to 2017. Dr. Goldstein served as the CFO of Loxo Oncology, Inc. between 2014 and 2015. From 2000 to 2005, Dr. Goldstein served as CFO of Vicuron Pharmaceuticals, Inc., raising over $250 million in equity financings, facilitating company partnership transactions, and participating in the M&A process when Vicuron was acquired by Pfizer, Inc. for $1.9 billion. Before joining Vicuron, he was Director of Venture Analysis at HealthCare Ventures.
Dr. Goldstein currently serves on the board of Directors of NeuBase Therapeutics (Nasdaq: NBSE) and Gain Therapeutics (Nasdaq: GANX). He previously served as a director for ADMA Biologics, Loxo Oncology, Esperion Therapeutics, Duranta Therapeutics, Cempra, and several private companies.
He received a Bachelor of Science in biological sciences from Stanford University, an MBA from Columbia Business School, and an M.D. from Yale School of Medicine.
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells to target disease. The company’s CTreg system is patent-pending and the first in the industry to overcome prior limitations of Treg cell therapies, allowing for serial infusions from a single manufacturing round. Through our proprietary TAI (Tregs Against Inflammation) and patent-pending iscEXO (immunosuppressive cell Exosome) platforms, Coya is focused on the advancement of disease-modifying approaches to address the significant unmet medical needs of patients with ALS, Frontotemporal Dementia, Parkinson’s, Alzheimer’s, and autoimmune diseases.
For more information: https://www.coyatherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.